The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation

Behavioural Brain Research

Volumn 230, Issue 1, 2012, Pages 291-298

  Fitzgerald, Paul J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

2 Deoxyglucose; Electrophysiology; Epilepsy; Functional brain imaging; Glutamate; Ketamine; Knockout mouse; MK 801; Neurotoxicity; NMDA receptor; Phencyclidine

Indexed keywords

DIZOCILPINE; GLUTAMIC ACID; KETAMINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTRANSMITTER; PHENCYCLIDINE; RECEPTOR SUBUNIT;

ELECTROPHYSIOLOGY; EPILEPSY; FEMALE; FUNCTIONAL NEUROIMAGING; HYPERPOLARIZATION; LEARNING; LIMBIC SYSTEM; MALE; MEMORY; MOUSE; NERVE CELL; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; SCHIZOPHRENIA;

ANIMALS; BRAIN; EPILEPSY; EXCITATORY AMINO ACID AGENTS; HUMANS; MICE; NEURAL INHIBITION; NEURAL PATHWAYS; NEURONS; NEUROTOXICITY SYNDROMES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84858445503     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.01.057     Document Type: Review

References (110)

1. Snyder S.H., Ferris C.D. Novel neurotransmitters and their neuropsychiatric relevance. Am J Psychiatry 2000, 157:1738-1751.
2. Dingledine R., Borges K., Bowie D., Traynelis S.F. The glutamate receptor ion channels. Pharmacol Rev 1999, 51:7-61.
3. Stewart G.R., Price M., Olney J.W., Hartman B.K., Cozzari C. N-Methylaspartate: an effective tool for lesioning basal forebrain cholinergic neurons of the rat. Brain Res 1986, 369:377-382.
4. Ikonomidou C., Mosinger J.L., Salles K.S., Labruyere J., Olney J.W. Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J Neurosci 1989, 9:2809-2818.
5. Freitas R.M., Sousa F.C., Viana G.S., Fonteles M.M. Effect of gabaergic, glutamatergic, antipsychotic and antidepressant drugs on pilocarpine-induced seizures and status epilepticus. Neurosci Lett 2006, 408:79-83.
6. Freeman F.G., Jarvis M.F., Duncan P.M. Phencyclidine raises kindled seizure thresholds. Pharmacol Biochem Behav 1982, 16:1009-1011.
7. Aram J.A., Martin D., Tomczyk M., Zeman S., Millar J., Pohler G., et al. Neocortical epileptogenesis in vitro: studies with N-methyl-d-aspartate, phencyclidine, sigma and dextromethorphan receptor ligands. J Pharmacol Exp Ther 1989, 248:320-328.
8. Grunze H.C., Rainnie D.G., Hasselmo M.E., Barkai E., Hearn E.F., McCarley R.W., et al. NMDA-dependent modulation of CA1 local circuit inhibition. J Neurosci 1996, 16:2034-2043.
9. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 2007, 27:11496-11500.
10. Zhang Y., Llinas R.R., Lisman J.E. Inhibition of NMDARs in the nucleus reticularis of the thalamus produces delta frequency bursting. Front Neural Circuits 2009, 3:20.
11. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001, 11:569-577.
12. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., et al. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005, 179:303-309.
13. Lewis D.A., Moghaddam B. Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol 2006, 63:1372-1376.
14. Rujescu D., Bender A., Keck M., Hartmann A.M., Ohl F., Raeder H., et al. A pharmacological model for psychosis based on N-methyl-d-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry 2006, 59:721-729.
15. Lisman J.E., Coyle J.T., Green R.W., Javitt D.C., Benes F.M., Heckers S., et al. Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia. Trends Neurosci 2008, 31:234-242.
16. Pittenger C., Sanacora G., Krystal J.H. The NMDAR as a therapeutic target in major depressive disorder. CNS & Neurol Disord-Drug Targets 2007, 6:101-115.
17. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1997, 17:2921-2927.
18. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
19. Jackson M.E., Homayoun H., Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci USA 2004, 101:8467-8472.
20. Di Lazzaro V., Oliviero A., Profice P., Pennisi M.A., Pilato F., Zito G., et al. Ketamine increases human motor cortex excitability to transcranial magnetic stimulation. J Physiol 2003, 547:485-496.
21. Kapur S., Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 2002, 7:837-844.
22. Li N., Lee B., Liu R.J., Banasr M., Dwyer J.M., Iwata M., et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010, 329:959-964.
23. Amir A., Fuchs P., Gamliel A., Reis M., Shainberg A. Effects of phencyclidine and analog drugs on acetylcholine receptor of cultured muscle cells. Biochem Pharmacol 1985, 34:949-954.
24. Maayani S., Weinstein H. Some structure activity relationships of phencyclidine derivatives as anticholinergic agents in vitro and in vivo. Prog Clin Biol Res 1979, 27:91-106.
25. Zukin S.R. Differing stereospecificities distinguish opiate receptor subtypes. Life Sci 1982, 31:1307-1310.
26. Hustveit O., Maurset A., Oye I. Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. Pharmacol Toxicol 1995, 77:355-359.
27. Bourn W.M., Yang D.J., Davisson J.N. Effect of ketamine enantiomers on sound-induced convulsions in epilepsy prone rats. Pharmacol Res Commun 1983, 15:815-824.
28. Lees G.J. Influence of ketamine on the neuronal death caused by NMDA in the rat hippocampus. Neuropharmacology 1995, 34:411-417.
29. Snyder E.W., Schlehuber C., Dustman R.E., Shearer D.E. Phencyclidine-induced alterations of rat electrophysiology. Brain Res Bull 1981, 7:249-253.
30. Chaturvedi A.K. Effects of mecamylamine, nicotine, atropine and physostigmine on the phencyclidine-induced behavioral toxicity. Pharmacol Biochem Behav 1984, 20:559-566.
31. O'Neill S.K., Bolger G.T. Phencyclidine and MK-801: a behavioral and neurochemical comparison of their interactions with dihydropyridine calcium antagonists. Brain Res Bull 1989, 22:611-616.
32. Feinberg I., Campbell I.G., Marrs J.C. Intraperitoneal dizocilpine induces cortical spike-wave seizure discharges in rats. Neurosci Lett 1995, 196:157-160.
33. Alldredge B.K., Lowenstein D.H., Simon R.P. Seizures associated with recreational drug abuse. Neurology 1989, 39:1037-1039.
34. Modica P.A., Tempelhoff R., White P.F. Pro- and anticonvulsant effects of anesthetics (Part II). Anesth Analg 1990, 70:433-444.
35. Datto C., Rai A.K., Ilivicky H.J., Caroff S.N. Augmentation of seizure induction in electroconvulsive therapy: a clinical reappraisal. J ECT 2002, 18:118-125.
36. Agarawal A., Raza M., Dhiraaj S., Saxena R., Singh P.K., Pandey R. Is ketamine a safe anesthetic for percutaneous liver biopsy in a liver transplant recipient immunosuppressed with cyclosporine?. Anesth Analg 2005, 100:85-86.
37. Sveinbjornsdottir S., Sander J.W., Upton D., Thompson P.J., Patsalos P.N., Hirt D., et al. The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 1993, 16:165-174.
38. Olney J.W. Excitotoxicity: an overview. Can Dis Wkly Rep 1990, 16(Suppl. 1E):47-58.
39. Olney J.W. Inciting excitotoxic cytocide among central neurons. Adv Exp Med Biol 1986, 203:631-645.
40. Clifford D.B., Olney J.W., Benz A.M., Fuller T.A., Zorumski C.F. Ketamine, phencyclidine, and MK-801 protect against kainic acid-induced seizure-related brain damage. Epilepsia 1990, 31:382-390.
41. Olney J.W., Labruyere J., Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989, 244:1360-1362.
42. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., St Peter H., et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol Psychiatry 1995, 38:788-796.
43. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991, 254:1515-1518.
44. Wozniak D.F., Dikranian K., Ishimaru M.J., Nardi A., Corso T.D., Tenkova T., et al. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: potential relevance to Alzheimer's disease. Neurobiol Dis 1998, 5:305-322.
45. Horak M., Chang K., Wenthold R.J. Masking of the endoplasmic reticulum retention signals during assembly of the NMDA receptor. J Neurosci 2008, 28:3500-3509.
46. Das S., Sasaki Y.F., Rothe T., Premkumar L.S., Takasu M., Crandall J.E., et al. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A. Nature 1998, 393:377-381.
47. Brody S.A., Nakanishi N., Tu S., Lipton S.A., Geyer M.A. A developmental influence of the N-methyl-d-aspartate receptor NR3A subunit on prepulse inhibition of startle. Biol Psychiatry 2005, 57:1147-1152.
48. Belforte J.E., Zsiros V., Sklar E.R., Jiang Z., Yu G., Li Y., et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010, 13:76-83.
49. Forrest D., Yuzaki M., Soares H.D., Ng L., Luk D.C., Sheng M., et al. Targeted disruption of NMDA receptor 1 gene abolishes NMDA response and results in neonatal death. Neuron 1994, 13:325-338.
50. Duncan G., Miyamoto S., Gu H., Lieberman J., Koller B., Snouwaert J. Alterations in regional brain metabolism in genetic and pharmacological models of reduced NMDA receptor function. Brain Res 2002, 951:166-176.
51. Halene T.B., Ehrlichman R.S., Liang Y., Christian E.P., Jonak G.J., Gur T.L., et al. Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 2009, 8:661-675.
52. Moy S.S., Perez A., Koller B.H., Duncan G.E. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res 2006, 1089:186-194.
53. Spooren W., Mombereau C., Maco M., Gill R., Kemp J.A., Ozmen L., et al. Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition. Psychopharmacology (Berl) 2004, 175:99-105.
54. Takeuchi T., Kiyama Y., Nakamura K., Tsujita M., Matsuda I., Mori H., et al. Roles of the glutamate receptor epsilon2 and delta2 subunits in the potentiation and prepulse inhibition of the acoustic startle reflex. Eur J Neurosci 2001, 14:153-160.
55. Miyamoto Y., Yamada K., Nagai T., Mori H., Mishina M., Furukawa H., et al. Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit. Eur J Neurosci 2004, 19:151-158.
56. Petrenko A.B., Kohno T., Wu J., Sakimura K., Baba H. Spontaneous hyperactivity in mutant mice lacking the NMDA receptor GluRepsilon1 subunit is aggravated during exposure to 0.1 MAC sevoflurane and is preserved after emergence from sevoflurane anaesthesia. Eur J Anaesthesiol 2008, 25:953-960.
57. Boyce-Rustay J.M., Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006, 31:2405-2414.
58. Higgins G.A., Ballard T.M., Huwyler J., Kemp J.A., Gill R. Evaluation of the NR2B-selective NMDA receptor antagonist Ro 63-1908 on rodent behaviour: evidence for an involvement of NR2B NMDA receptors in response inhibition. Neuropharmacology 2003, 44:324-341.
59. Miyamoto Y., Yamada K., Noda Y., Mori H., Mishina M., Nabeshima T. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit. J Neurosci 2002, 22:2335-2342.
60. Niemann S., Kanki H., Fukui Y., Takao K., Fukaya M., Hynynen M.N., et al. Genetic ablation of NMDA receptor subunit NR3B in mouse reveals motoneuronal and nonmotoneuronal phenotypes. Eur J Neurosci 2007, 26:1407-1420.
61. Hall B.J., Ripley B., Ghosh A. NR2B signaling regulates the development of synaptic AMPA receptor current. J Neurosci 2007, 27:13446-13456.
62. Cunningham M.O., Hunt J., Middleton S., LeBeau F.E., Gillies M.J., Davies C.H., et al. Region-specific reduction in entorhinal gamma oscillations and parvalbumin-immunoreactive neurons in animal models of psychiatric illness. J Neurosci 2006, 26:2767-2776.
63. French E.D. Effects of phencyclidine on ventral tegmental A10 dopamine neurons in the rat. Neuropharmacology 1986, 25:241-248.
64. French E.D. Effects of acute and chronic administration of phencyclidine on the A10 dopaminergic mesolimbic system: electrophysiological and behavioral correlates. Neuropharmacology 1988, 27:791-798.
65. French E.D., Ceci A. Non-competitive N-methyl-d-aspartate antagonists are potent activators of ventral tegmental A10 dopamine neurons. Neurosci Lett 1990, 119:159-162.
66. French E.D., Mura A., Wang T. MK-801, phencyclidine (PCP), and PCP-like drugs increase burst firing in rat A10 dopamine neurons: comparison to competitive NMDA antagonists. Synapse 1993, 13:108-116.
67. Wang T., French E.D. Effects of phencyclidine on spontaneous and excitatory amino acid-induced activity of ventral tegmental dopamine neurons: an extracellular in vitro study. Life Sci 1993, 53:49-56.
68. Villa A.E., Bajo Lorenzana V.M. Ketamine modulation of the temporal pattern of discharges and spike train interactions in the rat substantia nigra pars reticulata. Brain Res Bull 1997, 43:525-535.
69. Murase S., Mathe J.M., Grenhoff J., Svensson T.H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J Neural Transm Gen Sect 1993, 91:13-25.
70. West M.O. Anesthetics eliminate somatosensory-evoked discharges of neurons in the somatotopically organized sensorimotor striatum of the rat. J Neurosci 1998, 18:9055-9068.
71. Gratton A., Hoffer B.J., Freedman R. Electrophysiological effects of phencyclidine in the medial prefrontal cortex of the rat. Neuropharmacology 1987, 26:1275-1283.
72. Shi W.X., Zhang X.X. Dendritic glutamate-induced bursting in the prefrontal cortex: further characterization and effects of phencyclidine. J Pharmacol Exp Ther 2003, 305:680-687.
73. Kim M., Bickford P.C. Electrophysiological effects of phencyclidine and the sigma agonist ditolylguanidine in the cerebellum of the rat. Neuropharmacology 1992, 31:77-83.
74. Murase S., Nisell M., Grenhoff J., Svensson T.H. Decreased sensory responsiveness of noradrenergic neurons in the rat locus coeruleus following phencyclidine or dizocilpine (MK-801). Role of NMDA antagonism. Psychopharmacology (Berl) 1992, 109:271-276.
75. Duncan G.E., Leipzig J.N., Mailman R.B., Lieberman J.A. Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. Brain Res 1998, 812:65-75.
76. Duncan G.E., Moy S.S., Knapp D.J., Mueller R.A., Breese G.R. Metabolic mapping of the rat brain after subanesthetic doses of ketamine: potential relevance to schizophrenia. Brain Res 1998, 787:181-190.
77. Duncan G.E., Miyamoto S., Leipzig J.N., Lieberman J.A. Comparison of brain metabolic activity patterns induced by ketamine, MK-801 and amphetamine in rats: support for NMDA receptor involvement in responses to subanesthetic dose of ketamine. Brain Res 1999, 843:171-183.
78. Krenz N.R., Cooper R.M. A combined cobalt and C-14 2-deoxyglucose approach to antiepileptic drug assessment. Int J Neurosci 1996, 86:55-66.
79. Duncan G.E., Miyamoto S., Lieberman J.A. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther 2003, 305:999-1005.
80. Miyamoto S., Leipzig J.N., Lieberman J.A., Duncan G.E. Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. Neuropsychopharmacology 2000, 22:400-412.
81. Miyamoto S., Mailman R.B., Lieberman J.A., Duncan G.E. Blunted brain metabolic response to ketamine in mice lacking D(1A) dopamine receptors. Brain Res 2001, 894:167-180.
82. Wang Z.X., Ryan A.F., Woolf N.K. Pentobarbital and ketamine alter the pattern of 2-deoxyglucose uptake in the central auditory system of the gerbil. Hear Res 1987, 27:145-155.
83. Lahti A.C., Holcomb H.H., Medoff D.R., Tamminga C.A. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. Neuroreport 1995, 6:869-872.
84. Vollenweider F.X., Leenders K.L., Scharfetter C., Antonini A., Maguire P., Missimer J. Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG). Eur Neuropsychopharmacol 1997, 7:9-24.
85. Abel K.M., Allin M.P., Kucharska-Pietura K., Andrew C., Williams S., David A.S., et al. Ketamine and fMRI BOLD signal: distinguishing between effects mediated by change in blood flow versus change in cognitive state. Hum Brain Mapp 2003, 18:135-145.
86. Northoff G., Richter A., Bermpohl F., Grimm S., Martin E., Marcar V.L., et al. NMDA hypofunction in the posterior cingulate as a model for schizophrenia: an exploratory ketamine administration study in fMRI. Schizophr Res 2005, 72:235-248.
87. Deakin J.F., Lees J., McKie S., Hallak J.E., Williams S.R., Dursun S.M. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry 2008, 65:154-164.
88. Burdett N.G., Menon D.K., Carpenter T.A., Jones J.G., Hall L.D. Visualisation of changes in regional cerebral blood flow (rCBF) produced by ketamine using long TE gradient-echo sequences: preliminary results. Magn Reson Imaging 1995, 13:549-553.
89. Littlewood C.L., Jones N., O'Neill M.J., Mitchell S.N., Tricklebank M., Williams S.C. Mapping the central effects of ketamine in the rat using pharmacological MRI. Psychopharmacology (Berl) 2006, 186:64-81.
90. Gozzi A., Large C.H., Schwarz A., Bertani S., Crestan V., Bifone A. Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine. Neuropsychopharmacology 2008, 33:1690-1703.
91. Gozzi A., Schwarz A., Crestan V., Bifone A. Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine. Magn Reson Imaging 2008, 26:999-1006.
92. Gozzi A., Herdon H., Schwarz A., Bertani S., Crestan V., Turrini G., et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat. Psychopharmacology (Berl) 2008, 201:273-284.
93. Aalto S., Ihalainen J., Hirvonen J., Kajander J., Scheinin H., Tanila H., et al. Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man. Psychopharmacology (Berl) 2005, 182:375-383.
94. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
95. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006, 63:856-864.
96. Mayberg H.S., Lozano A.M., Voon V., McNeely H.E., Seminowicz D., Hamani C., et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005, 45:651-660.
97. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 1999, 33:523-533.
98. Bannerman D.M., Deacon R.M., Brady S., Bruce A., Sprengel R., Seeburg P.H., et al. A comparison of GluR-A-deficient and wild-type mice on a test battery assessing sensorimotor, affective, and cognitive behaviors. Behav Neurosci 2004, 118:643-647.
99. Vekovischeva O.Y., Aitta-Aho T., Echenko O., Kankaanpaa A., Seppala T., Honkanen A., et al. Reduced aggression in AMPA-type glutamate receptor GluR-A subunit-deficient mice. Genes Brain Behav 2004, 3:253-265.
100. Wiedholz L.M., Owens W.A., Horton R.E., Feyder M., Karlsson R.M., Hefner K., et al. Mice lacking the AMPA GluA1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors. Mol Psychiatry 2008, 13:631-640.
101. Fitzgerald P.J., Barkus C., Feyder M., Wiedholz L.M., Chen Y.C., Karlsson R.M., et al. Does gene deletion of AMPA GluA1 phenocopy features of schizoaffective disorder?. Neurobiol Dis 2010, 40:608-621.
102. Shaltiel G., Maeng S., Malkesman O., Pearson B., Schloesser R.J., Tragon T., et al. Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 2008, 13:858-872.
103. Wainai T., Takeuchi T., Seo N., Mishina M. Regulation of acute nociceptive responses by the NMDA receptor GluRepsilon2 subunit. Neuroreport 2001, 12:3169-3172.
104. Fajardo G., Zhao M., Powers J., Bernstein D. Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. J Mol Cell Cardiol 2006, 40:375-383.
105. Winstanley C.A., Theobald D.E., Dalley J.W., Glennon J.C., Robbins T.W. 5-HT2A and 5-HT2C receptor antagonists have opposing effects on a measure of impulsivity: interactions with global 5-HT depletion. Psychopharmacology (Berl) 2004, 176:376-385.
106. Fletcher P.J., Tampakeras M., Sinyard J., Higgins G.A. Opposing effects of 5-HT(2A) and 5-HT(2C) receptor antagonists in the rat and mouse on premature responding in the five-choice serial reaction time test. Psychopharmacology (Berl) 2007, 195:223-234.
107. Robinson E.S., Dalley J.W., Theobald D.E., Glennon J.C., Pezze M.A., Murphy E.R., et al. Opposing roles for 5-HT2A and 5-HT2C receptors in the nucleus accumbens on inhibitory response control in the 5-choice serial reaction time task. Neuropsychopharmacology 2008, 33:2398-2406.
108. Boulougouris V., Glennon J.C., Robbins T.W. Dissociable effects of selective 5-HT2A and 5-HT2C receptor antagonists on serial spatial reversal learning in rats. Neuropsychopharmacology 2008, 33:2007-2019.
109. Halberstadt A.L., van der Heijden I., Ruderman M.A., Risbrough V.B., Gingrich J.A., Geyer M.A., et al. 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 2009, 34:1958-1967.
110. Skolnick P., Popik P., Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009, 30:563-569.